Decreased hearing after combined modality therapy for head and neck cancer

2006 ◽  
Vol 27 (2) ◽  
pp. 76-80 ◽  
Author(s):  
Susan E. Pearson ◽  
Abby C. Meyer ◽  
George L. Adams ◽  
Frank G. Ondrey
1984 ◽  
Vol 2 (7) ◽  
pp. 804-810 ◽  
Author(s):  
S H Krasnow ◽  
M H Cohen ◽  
A Johnston-Early ◽  
M L Citron ◽  
B E Fossieck ◽  
...  

As part of a combined modality treatment program using chemotherapy, surgery, and/or radiotherapy, 25 patients with previously untreated stage III or IV head and neck cancer received initial combination chemotherapy. Pathologically confirmed complete remission was noted in nine patients (36%). The overall objective major response rate (with all patients included in analysis) was 68%. The chemotherapy regimen included bleomycin, cisplatin, vinblastine, methotrexate, and 5-fluorouracil. A novel concept of drug scheduling was used, based on chemotherapy-induced improvement in RBC deformability. The underlying concept is that improved RBC deformability results in improved capillary blood flow and thereby, increased drug delivery to tumor cells. Treatment resulted in moderate hematologic and renal toxicity with no treatment-related deaths. This exceptionally high, pathologically confirmed complete response rate will hopefully provide a mechanism by which combined modality therapy can adequately be tested for its ability to prolong survival of patients with advanced head and neck cancer.


1986 ◽  
Vol 152 (4) ◽  
pp. 451-455 ◽  
Author(s):  
John R. Jacobs ◽  
Julie Kish ◽  
John F. Ensley ◽  
Khurshid Ahmad ◽  
Arthur Weaver ◽  
...  

Head & Neck ◽  
2004 ◽  
Vol 26 (5) ◽  
pp. 447-455 ◽  
Author(s):  
Athanassios Argiris ◽  
Kerstin M. Stenson ◽  
Bruce E. Brockstein ◽  
Bharat B. Mittal ◽  
Harold Pelzer ◽  
...  

1980 ◽  
Vol 140 (4) ◽  
pp. 549-552 ◽  
Author(s):  
Arthur Weaver ◽  
John J.K. Loh ◽  
Henry Vandenberg ◽  
William Powers ◽  
Susan Fleming ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document